Assessing the Cost-Effectiveness of Molecular Targeted Therapies and Immune Checkpoint Inhibitors

Abstract Molecular targeted therapies and immune checkpoint inhibitors have in recent years been transforming the care of many cancer patients. This chapter compares twenty-one appraisals molecular non-small-cell lung cancer, comprising six EGFR-TK (gefitinib, erlotinib, afatinib, necitumumab, osimertinib dacomitinib), five ALK (crizotinib, ceritinib, alectinib, brigatinib lorlatinib) two ROS1 (crizotinib entrectinib), with fifteen used treatment anti-PD-1 agents nivolumab pembrolizumab, anti-PD-L1 atezolizumab durvalumab. Differences respect to economic evaluation, such as, terms clinical evidence underlying modelling cost-effectiveness, differences observed life-extending end-of-life status inclusion Cancer Drugs Fund, are highlighted. The between appraisal types therapy derive from more limited data restricted application medicines. study decision making oncology drugs is likely be increasingly relevant a much wider range medicines, as differential weighting QALYs use managed access schemes extended beyond drugs.